Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis. A report of two cases.
Anti-DNA topoisomerase I (anti-topo I) antibody profiles were compared before and after lung cancer in 2 patients with systemic sclerosis (SSc). Both patients developed adenocarcinoma of the lung late in the course of SSc and died of the cancer. Anti-topo I antibody levels, determined by double immunodiffusion and enzyme-linked immunosorbent assay, increased markedly at the time of diagnosis of lung cancer. Furthermore, patients' sera obtained after lung cancer reacted with multiple epitopes on the entire topo I molecule, some of which had not previously been recognized. These results further support the concept that anti-topo I antibody production in SSc patients is due to an antigen-driven process.
Kuwana
M
M
Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Fujii
T
T
Mimori
T
T
Kaburaki
J
J
D000230:Adenocarcinoma / Q000209:etiology / Q000276:immunology*; D000328:Adult; D000906:Antibodies / Q000097:blood; D001323:Autoantibodies / Q000097:blood*; D004264:DNA Topoisomerases, Type I / Q000276:immunology*; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D008175:Lung Neoplasms / Q000209:etiology* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000150:complications* / Q000276:immunology*
D000906:Antibodies; D001323:Autoantibodies; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D004264:DNA Topoisomerases, Type I